These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19704160)

  • 1. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.
    William WN; Gold KA; Kim ES
    Ann Oncol; 2009 Sep; 20(9):1455-1457. PubMed ID: 19704160
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer.
    Natale RB
    Semin Oncol; 2004 Jun; 31(3 Suppl 9):23-30. PubMed ID: 15206079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary on ZD1839 (Iressa) in non small cell lung cancer.
    Ranson M; Thatcher N
    Lung Cancer; 2003 Apr; 40(1):77-8. PubMed ID: 12660010
    [No Abstract]   [Full Text] [Related]  

  • 4. Gefitinib for refractory advanced non-small-cell lung cancer.
    Moriguchi H; Kim TY; Sato C
    Lancet; 2006 Jan; 367(9507):299-300. PubMed ID: 16443032
    [No Abstract]   [Full Text] [Related]  

  • 5. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
    Reck M; Gatzemeier U
    Respir Med; 2005 Mar; 99(3):298-307. PubMed ID: 15733505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.
    Iurisci I; Rich T; Lévi F; Innominato PF; Tinari N; Irtelli L; De Tursi M; Grassadonia A; Iacobelli S
    J Clin Oncol; 2007 Jun; 25(16):e17-9. PubMed ID: 17538154
    [No Abstract]   [Full Text] [Related]  

  • 7. Improvements in quality of life and disease-related symptoms in patients with advanced non-small cell lung cancer treated with gefitinib.
    Zhang XT; Li LY; Wang SL; Mu XL; Wang MZ; Song W
    Chin Med J (Engl); 2005 Oct; 118(19):1661-4. PubMed ID: 16232354
    [No Abstract]   [Full Text] [Related]  

  • 8. Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.
    Dahlberg SE; Gray RJ; Johnson BE
    J Clin Oncol; 2008 Sep; 26(26):4233-5. PubMed ID: 18779608
    [No Abstract]   [Full Text] [Related]  

  • 9. Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?
    Vasile E; Tibaldi C; Falcone A
    Ann Oncol; 2009 Apr; 20(4):790-1. PubMed ID: 19264832
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
    Price N; Belani C
    Clin Lung Cancer; 2005 Jan; 6(4):214-6. PubMed ID: 15694012
    [No Abstract]   [Full Text] [Related]  

  • 11. Gefitinib or docetaxel in advanced non-small-cell lung cancer.
    Cullen M; Thatcher N
    Lancet; 2008 Nov; 372(9652):1785-6. PubMed ID: 19027472
    [No Abstract]   [Full Text] [Related]  

  • 12. [Molecular factors related to gefitinib efficacy in advanced non-small cell lung cancer].
    Lv P; Zhou T
    Zhongguo Fei Ai Za Zhi; 2010 Mar; 13(3):247-53. PubMed ID: 20673523
    [No Abstract]   [Full Text] [Related]  

  • 13. Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients?
    Fujiwara K; Kiura K; Gemba K; Ogata Y; Hotta K; Kishino D; Tabata M; Ueoka H; Tanimoto M
    Anticancer Res; 2005; 25(1B):547-9. PubMed ID: 15816627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
    Shao YY; Lin CC; Yang CH
    Discov Med; 2010 Jun; 9(49):538-45. PubMed ID: 20587343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib does not increase survival in lung cancer patients.
    Golsteyn RM
    Drug Discov Today; 2005 Mar; 10(6):381. PubMed ID: 15808815
    [No Abstract]   [Full Text] [Related]  

  • 17. Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.
    Passaro A; Alesini D; Pochesci A; Cortesi E
    Anticancer Agents Med Chem; 2014 Jun; 14(5):646-50. PubMed ID: 23140355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
    Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
    [No Abstract]   [Full Text] [Related]  

  • 19. Gefitinib: phoenix from the flames.
    Lancet Oncol; 2009 Aug; 10(8):737. PubMed ID: 19647191
    [No Abstract]   [Full Text] [Related]  

  • 20. Gefitinib.
    Muhsin M; Graham J; Kirkpatrick P
    Nat Rev Drug Discov; 2003 Jul; 2(7):515-6. PubMed ID: 12841190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.